Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors
| Autor: | J.-J. Patard, Karim Fizazi, Christophe Massard, S. Droupy, B. Albouy, Marine Gross-Goupil, S. Leborgne, Bernard Escudier, T. Bessede |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty Sexual Behavior Population Angiogenesis Inhibitors Erectile Dysfunction Quality of life Internal medicine Sexual medicine medicine Humans Molecular Targeted Therapy education Carcinoma Renal Cell Aged Retrospective Studies Gynecology education.field_of_study business.industry Hematology Drug holiday Middle Aged medicine.disease Kidney Neoplasms Sexual desire Erectile dysfunction Oncology Sex life Sexual function business |
| Zdroj: | Annals of Oncology. 22:2320-2324 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdq766 |
| Popis: | Background The advanced renal cell carcinoma (RCC) affects patients mainly ∼60 years of age and who may have an active sex life. The objective of the study was to investigate possible sexual disorders in a male population with advanced RCC treated with a molecular targeted therapy (MTT). Patients and methods Thirty-eight male patients with a stabilized advanced RCC on MTT were proposed a personal interview about their sexual life, filled in the International Index of Erectile Function (IIEF) auto-questionnaire, and were reassessed if the treatment was modified. Results This is the first evaluation of sexual life while on MTT. For 64% of the patients (median age 59 years, treatment duration 12 months), the quality of their sexual life was considered important. The scores of the IIEF were reduced from 30% to 60% in erectile function, intercourse satisfaction, orgasmic function, sexual desire, and overall satisfaction. The erectile dysfunction was more severe in the MTT population compared with age-stratified general or urological populations. The disorders were reversible in a few cases after treatment interruption. Conclusions Patients on MTT for an advanced RCC experience a decline of sexual activity. Onco-urologists should systematically inform, screen, initiate management, and refer patients to sexual medicine physicians. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|